Clinical Trials Logo

Atypical Endometrial Hyperplasia clinical trials

View clinical trials related to Atypical Endometrial Hyperplasia.

Filter by:

NCT ID: NCT06390904 Recruiting - Obesity Clinical Trials

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients

Start date: July 13, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

To investigate the efficacy of Gonadotropin-releasing Hormone Agonist (GnRHa) plus letrozole in obese progestin-insensitive atypical endometrial hyperplasia (EAH) patients.

NCT ID: NCT06379113 Recruiting - Obesity Clinical Trials

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

Start date: July 13, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

To investigate the efficacy of GnRHa plus letrozole in obese progestin-insensitive EEC patients.

NCT ID: NCT05675787 Recruiting - Clinical trials for Atypical Endometrial Hyperplasia

Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

Start date: January 6, 2023
Phase: Phase 2
Study type: Interventional

To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.

NCT ID: NCT05647109 Recruiting - Clinical trials for Atypical Endometrial Hyperplasia

Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer

Start date: September 1, 2021
Phase:
Study type: Observational [Patient Registry]

To construct a prediction model of progesterone sensitivity in patients with endometrial cancer treated with fertility preservation

NCT ID: NCT05316935 Recruiting - Clinical trials for Endometrial Neoplasms

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Start date: July 13, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

To investigate the efficacy of GnRHa plus letrozole vs Diane-35 plus metformin in non-obese progestin-insensitive early-stage endometrial cancer (EEC) and atypical hyperplasia(EAH) patients asking for conservative treatment.

NCT ID: NCT05316493 Recruiting - Clinical trials for Overweight and Obesity

Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia

Start date: June 13, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

To investigate the efficacy of weight management plus levonorgestrel intrauterine system (LNG-IUS) or megestrol acetate (MA) in obese patients with endometrial atypical hyperplasia (EAH) asking for conservative therapy.

NCT ID: NCT05172999 Recruiting - Obesity Clinical Trials

Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia

Start date: January 8, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

To study if polyethylene glycol loxenatide plus levonorgestrel-releasing intrauterine system (LNG-IUS) will improve response rates in patients with endometrial atypical hyperplasia.

NCT ID: NCT05051722 Recruiting - Ovarian Cancer Clinical Trials

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

ECHO
Start date: August 3, 2021
Phase:
Study type: Observational

The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in tampon-collected vaginal fluid and 2) ovarian cancer (OC) in plasma and tampon-collected vaginal fluid. Additionally, it defines necessary Phase I MDM-based cancer detection and exploratory aims to test novel cervical cancer (CC) MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.er detection and exploratory aims to test novel cervical cancer MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.

NCT ID: NCT04683237 Withdrawn - Obese Clinical Trials

Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia

Start date: March 20, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

To investigate the efficacy of liraglutide plus megestrol acetate in obesity patients with atypical endometrial hyperplasia (AEH)

NCT ID: NCT04607252 Terminated - Clinical trials for Atypical Endometrial Hyperplasia

Metformin Plus Megestrol Acetate as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia

Start date: January 11, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

To verify whether metformin could improve the effect of progestin as fertility-sparing treatment in patients with atypical endometrial hyperplasia(AEH).